0001209191-23-052389.txt : 20231006 0001209191-23-052389.hdr.sgml : 20231006 20231006215910 ACCESSION NUMBER: 0001209191-23-052389 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231005 FILED AS OF DATE: 20231006 DATE AS OF CHANGE: 20231006 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DAVIS STEPHEN CENTRAL INDEX KEY: 0001131146 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50768 FILM NUMBER: 231315313 MAIL ADDRESS: STREET 1: ACADIA PHARMACEUTICALS INC. STREET 2: 12830 EL CAMINO REAL, SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001070494 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 061376651 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12830 EL CAMINO REAL STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-558-2871 MAIL ADDRESS: STREET 1: 12830 EL CAMINO REAL STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-10-05 0 0001070494 ACADIA PHARMACEUTICALS INC ACAD 0001131146 DAVIS STEPHEN C/O ACADIA PHARMACEUTICALS INC. 12830 EL CAMINO REAL, SUITE 400 SAN DIEGO CA 92130 1 1 0 0 CEO 0 Common Stock 2023-10-05 4 M 0 103999 A 140694 D Common Stock 2023-10-06 4 S 0 51563 21.96 D 89131 D Restricted Stock Units 2023-10-06 4 M 0 103999 0.00 D Common Stock 103999 173332 D Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Includes 1,594 shares acquired by the Reporting Person under the Issuer's 2004 Employee Stock Purchase Plan on May 15, 2023. The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Subject to accelerated vesting in certain circumstances, the restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. /s/ Austin D. Kim, Attorney-in-Fact 2023-10-06